| LBCTR2019020191 | CAIN457M2302 | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNRISE) | Interventional | Complete | 08/02/2019 |
| LBCTR2019010184 | CLEE011A2404 | COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease | COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease | Interventional | Complete | 11/01/2019 |
| LBCTR2019080232 | CLEE011F2301 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer ( MONALEESA 3) | A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment | Interventional | Complete | 06/05/2019 |
| LBCTR2023095432 | PIDMR3 | Evaluation of Pharmacist-Initiated Discharge Medication Reconciliation and Patient Counseling Procedures in the Emergency Department | Evaluation of Pharmacist-Initiated Discharge Medication Reconciliation and Patient Counseling Procedures in the Emergency Department | Interventional | Complete | 08/11/2023 |
| LBCTR2023065377 | N/A | Impact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in Lebanon | Impact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in Lebanon | Observational | Complete | 14/06/2023 |
| LBCTR2019020194 | CLEE011E2301 | A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer. ( MONALEESA 7) | A phase III randomized , double blind, placebo controlled study of LEE011or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI)and goserelin for the treatment of premenopausal women with hormone receptor positive, HER 2 negative, advanced breast cancer. | Interventional | Complete | 15/02/2019 |
| LBCTR2019030205 | MO40628 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER_ EUDRACT NUMBER: 2018-002153-30 | Interventional | Complete | 27/02/2019 |
| LBCTR2019050229 | CLEE011A2301 | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) | A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease | Interventional | Complete | 03/05/2019 |
| LBCTR2019040221 | CACZ885T2301 | Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A | A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) | Interventional | Complete | 04/04/2019 |
| LBCTR2023125487 | LAU.SOP.ER1.14/Sep/2022 | Pharmacist-Led Medication Reconciliation Upon Discharge from the Orthopedic Surgery Department | Pharmacist-Led Medication Reconciliation Upon Discharge from the Orthopedic Surgery Department: An Interventional Randomized Controlled Trial | Interventional | Complete | 19/12/2023 |